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Abstract: The MAP3-kinase TGF-beta-activated kinase 1 (TAK1) crit-
ically modulates innate and adaptive immune responses and connects
cytokine stimulation with activation of inﬂammatory signaling path-
ways. Here, we report that conditional ablation of TAK1 in liver paren-
chymal cells (hepatocytes and cholangiocytes) causes hepatocyte
dysplasia and early-onset of hepatocarcinogenesis, coinciding with bil-
iary ductopenia and cholestasis. TAK1-mediated cancer suppression is
exerted through activating NF-kappaB in response to tumor necrosis
factor (TNF) and through preventing Caspase-3-dependent hepatocyte
and cholangiocyte apoptosis. Moreover, TAK1 suppresses a procarcin-
ogenic and pronecrotic pathway, which depends on NF-kappaB-inde-
pendent functions of the I kappaB-kinase (IKK)-subunit NF-kappaB
essential modulator (NEMO). Therefore, TAK1 serves as a gatekeeper
for a protumorigenic, NF-kappaB-independent function of NEMO in
parenchymal liver cells.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Hepatocellular cancer (HCC) is the ﬁfth most common cancer yet
the third most common cause of cancer related death with a
5-year survival rate of just below 10% [1]. Viral infections, obes-
ity, or alcohol abuse trigger chronic liver damage leading to
inﬂammation and ﬁbrosis and thus substantially increase the risk
to develop HCC [2]. Using complex genetic mouse models, severalJournal of Hepatology 20
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E-mail address: ﬂorian.greten@lrz.tum.debeen identiﬁed in recent years helping to improve our under-
standing of the exact underlying molecular mechanisms of these
processes.
One important player in both inﬂammation and cancer is the
transcription factor NF-jB [3]. Classical NF-jB activation is con-
trolled by the multi-protein complex IjB-kinase, which is com-
prised of the two catalytical subunits IKKa and IKKb as well as
the regulatory subunit IKKc (NTVO). IKKb-dependent NF-jB acti-
vation is considered to provide pro-tumorigenic properties by
suppressing cell death in tumor cells in a cell autonomous man-
ner and by production of pro-inﬂammatory, pro-proliferative fac-
tors in myeloid cells that can act on tumor cells in a paracrine
fashion [4]. However, during the pathogenesis of HCC, NF-jB’s
particular importance for hepatocyte survival may confer a
liver-speciﬁc anti-tumorigenic function [5]. Because of the regen-
erative capacity of the liver, enhanced hepatocyte apoptosis
caused by the loss of NF-jB function results in a stronger c-Jun
N-terminal kinase (JNK) dependent compensatory proliferative
response and ultimately in a higher tumor load. This was docu-
mented both in a model of diethylnitrosamine (DEN) induced
HCC in the case of liver speciﬁc IKKb-deﬁciency [6] as well as
in mice with a hepatocyte restricted loss of IKKc, that even spon-
taneously developed HCC [7]. It was suggested that, in the case of
NF-jB deﬁciency, transcription of anti-oxidant scavengers was
suppressed causing an accumulation of reactive oxygen species
(ROS) which in turn led to the inhibition of MAP kinase phospha-
tases (MKPs) and ultimately to the sustained activation of JNK [8].
Accordingly, treatment with an anti-oxidant or genetic ablation
of JNK1 reversed the increased susceptibility to DEN-induced
HCC in NF-jB deﬁcient animals [6,7,9].
Now another player has entered the complex ﬁeld of NF-jB/
JNK interaction in the pathogenesis of HCC: transforming growth
factor (TGF) b-activated kinase 1 (TAK1). TAK1 belongs to the
mitogen-activated protein kinase kinase kinase (MAP3K) family
and is activated by various inﬂammatory mediators including
TNFa, IL-1 as well as LPS. TAK1 is involved in the stimulation of
the IKK complex as well as JNK and p38 [10].
In a study recently published in Cancer Cell, Bettermann et al.
addressed the function of TAK1 in HCC development [11]. Loss of
TAK1 in liver parenchymal cells led to spontaneous hepatitis,
hepatocyte dysplasia, liver ﬁbrosis, and spontaneous death of
the animals within 40 weeks. Importantly, almost 90% of the
mice had developed true HCCs characterized by marked chromo-
























Fig. 1. TAK1 and IKKc control two different pathways that ultimately prevent
JNK activation. The ﬁrst one depends on NF-jB and leads to the transcription of
genes encoding anti-oxidant proteins that suppress ROS accumulation. Therefore,
MAP kinase phosphatases can terminate JNK activation. In case of IKKb or IKKc
loss, ROS block MKPs, which leads to sustained JNK activation and increased cell
death and thereby to the release of pro-inﬂammatory cytokines, such as IL-1a,
which activate adjacent Kupffer cells to secrete pro-inﬂammatory and mitogenic
products that stimulate a compensatory hyperproliferation. Now, Bettermann
and colleagues demonstrated that TAK1 can also suppress MKK4 and MMK7 and
thereby JNK activity. Surprisingly, IKKc is an essential component in this cascade.
However, in case of TAK1 deﬁciency, JNK activation is higher and tissue damage is
stronger and consequently HCC development more rapid in comparison to mice
with hepatocyte restricted IKKc-deletion. Nevertheless, concomitant loss of TAK1
and IKKc in hepatocytes suppressed elevated MKK4/MKK7-JNK signaling
observed in TAK1 single knockout cells thus clearly supporting an IKKc-mediated
function independently of NF-jB signaling. Which the additional players in this
cascade are or what the role of p38 is, remains to be analyzed.
International Hepatologywell as H19. Similar ﬁndings were also reported by Inokuchi et al.
in an independently conducted study [12]. Both groups suggested
hepatocyte death, consecutive inﬂammation, and compensatory
proliferation associated with elevated JNK activation as the722 Journal of Hepatology 201underlying cause for HCC development in TAK1-deﬁcient livers.
This strongly resembled the phenotype observed in mice with a
hepatocyte-restricted loss of NF-jB.
However, Bettermann and colleagues suggested that, unlike in
NF-jB deﬁcient hepatocytes, in TAK1-deﬁcient livers JNK activa-
tion was dependent on the increased phosphorylation of MKK4
and MKK7. Accordingly, nevertheless very surprisingly, com-
pound mutants with concomitant loss of IKKc and TAK1 in the
liver parenchymal cells, decreased MKK4/MKK7 and JNK activa-
tion and prevented necrosis, dysplasia, and most importantly
HCC development, when double mutant mice were monitored
up to 50 weeks. Thus, while in a TAK1 proﬁcient background IKKc
acts as a NF-jB dependent tumor suppressor, its role switches to
a NF-jB independent tumor promoter once TAK1 function is
ablated. Thus, these results clearly demonstrate for the ﬁrst time,
functionally, a NF-jB independent function of IKKc that is extre-
mely relevant for the pathogenesis of HCC. The fact that IKKc is
involved in the regulation of other NF-jB independent signaling
pathways may also help to explain previous ﬁndings in mice with
a cell speciﬁc deletion of IKKc that had not been observed when
IKKb was absent [6,7] (Fig. 1).
However, the exact underlying molecular mechanisms linking
TAK1/IKKc to MKK4/MKK7 regulation still remain to be eluci-
dated. Considering that also hepatocyte speciﬁc loss of p38 is
associated with increased phosphorylation of MKK4 and MKK7,
elevated JNK activation and HCC development [13] it may also
be interesting to address whether this MAP kinase is involved
in this interplay. It will be essential to fully understand the cell
autonomous complex interaction of various inﬂammatory and
stress signaling pathways, which is further inﬂuenced by para-
crine effects mediated by Kupffer cells and hepatic stellate cells
in the vicious cycle of hepatocyte death, Kupffer cell activation
and subsequent compensatory hyperproliferation. Importantly,
in contrast to DEN-induced hepatic tumors, TAK1 deﬁcient HCC
develop in the context of liver ﬁbrosis, as it is commonly found
in human HCC. The current results by Bettermann et al. open,
therefore, a completely new avenue and promise very exciting
results that are still lying ahead of us. Thus, these new ﬁndings
comprise a very important step on the long way to discover
urgently needed new therapeutic targets and effective therapy
regimens for this deadly disease.Conﬂict of interest
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